Gyre Therapeutics appoints Dan Weng, M.D. to Board of Directors

GYRE THERAPEUTICS, INC.

Dan Weng appointed as Class II director effective August 18, 2025.
Dr. Weng has extensive CRO leadership, including CEO of Medelis and former Chairman/CEO of EPS International.
Appointment supported by parent company GNI Group Ltd. (TSE: 2160).
He will receive standard non-employee director compensation per company policy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.